Project Grant R01HL179083
Award Date
5/1/25
Completion Date
3/31/30
Dollars Obligated
$705K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The $2,009,636 award to The Leland Stanford Junior University will fund research to investigate the regulatory mechanisms governing smooth muscle cell phenotype transitions and their relationship to vascular disease risk. Key research objectives include mapping the epigenomic...
This $717,246 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The research team at The Leland Stanford Junior University will leverage a multiple myeloma mouse model, human induced pluripotent stem cells, CRISPR screening, single-cell RNA sequencing, and computational approaches to identify pathogenic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research to optimize surgical procedures for congenital aortic valve disease. The $181,392 award to The Leland Stanford Junior University aims to leverage computational modeling and in vitro testing to guide the design of two promising surgical interventions: bicuspidization repair and bioprinted valve replacement. The...
The National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). This grant, effective July 1, 2024 through November 30, 2026, will support UCSF's research to adapt cell-based therapies for the treatment of pulmonary fibrosis. As a leading academic medical research institution, UCSF...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,102,957 to The Leland Stanford Junior University to conduct research on the linkage between cancer and cardiovascular disease. The research aims to precisely determine if cancer directly promotes cardiovascular disease and identify potential therapies. The interdisciplinary team will utilize population genetics, cardio-oncology, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $381,250 to Clemson University to conduct research on identifying novel atheroprotective mechanisms related to vascular smooth muscle cell cholesterol efflux. The research aims to rigorously analyze the potential atheroprotective impacts of increased expression of the ABC transporters ABCA1 and ABCG1 in...
This $107,948 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to engineer hematopoietic stem and progenitor cells to produce B cells that secrete antibodies targeting PCSK9, a key regulator of cholesterol levels. The research, conducted at Stanford University from June 2025 through August 2028, will evaluate the safety and efficacy of this gene-targeted antibody (GT-AB) approach as a potential lifelong treatment for...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research investigating the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM). The $159,512 grant, awarded to The Leland Stanford Junior University, will examine how impaired protein homeostasis leads to cardiac dysfunction in DCM using patient-derived induced pluripotent stem cell-derived...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $686,640 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant, titled "Finding and Pushing the Limits of Macrophage Efferocytosis in Atherosclerosis," aims to uncover new insights into therapeutic opportunities targeting macrophage efferocytosis (the clearance of dead cells) to mitigate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,314.00 to The Leland Stanford Junior University to define the innate immune cell profile involved in the development of inhibitory antibodies against infused coagulation protein factor VIII (FVIII) in persons with hemophilia A. The research aims to 1) characterize the cytokine microenvironment and CD4+ T cell...